A-TANGO: Novel combinatorial treatment of acute-on-chronic liver failure
Goal: About 30,000 Europeans die every year from alcohol-related cirrhosis. In its final stages, the disease leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy “G-TAK”. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.
Scientific Coordination: Prof. Dr. Rajiv Jalan
Principal Investigator: Dr. med. Cornelius Engelmann
Science Communication: Dr. Nina Donner
Project Management: concentris research management gmbh
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 945096. This project log reflects only the author's view and the European Commission is not responsible for any use that may be made of the information it contains.
Date: 1 March 2021
- Rajiv Jalan's Lab